Weekly Policy Update: End the Device Tax

Friday, August 09, 2019


Weekly Policy Update: Senate Finance Committee Advances Drug Pricing Package

Friday, July 26, 2019

On Thursday, the Senate Finance Committee advanced a major legislative package that includes substantial changes to Medicare and Medicaid drug reimbursement. The bill, the Prescription Drug Pricing Reduction Act, passed the Committee by a vote of 19-9 and will be considered by the full Senate in the fall. 

Weekly Policy Update: We Work For Health Summit—CBSA Urges Federal Lawmakers to Promote Medical Innovation and Protect Patient Access

Monday, July 22, 2019


Weekly Policy Update: Trump Administration Pulls Rebate Rule

Monday, July 15, 2019

Last week the Trump Administration withdrew their proposed rebate rule that would have required manufacturer rebates to be passed through to patients in Part D and other government programs.  

Weekly Policy Update: Drug Pricing Bills Pass Key Senate Committees

Monday, July 08, 2019


Weekly Policy Update: New Economic Forecast Indicates Increase in Expected Revenue Above the TABOR Cap

Thursday, June 20, 2019
Continue Reading

Weekly Policy Update: CBSA Submits Comment Letter to Senate Finance Committee’s Health Task Force Urging Repeal of the Medical Device Excise Tax

Friday, June 14, 2019


Weekly Policy Update: CBSA Attends the 2019 BIO International Convention

Monday, June 10, 2019

Last week CBSA President and CEO Jennifer Jones Paton and Vice President Emily Roberts attended the 2019 BIO International Convention in Philadelphia. The event brings together over 16,000 attendees from around the world for educational sessions, networking events, and partnering meetings. For the CBSA team, it’s a great opportunity to connect with industry partners, biotechnology companies, and other state associations to discuss collaboration opportunities and share best practices.  

Improving the Reimbursement Landscape for Medical Technology Innovators

Friday, May 24, 2019

CBSA continues to work with Congress and federal policymakers to improve the reimbursement landscape for medical technology innovators. Even when groundbreaking and innovative technologies meet FDA’s rigorous standards, device manufacturers face other significant hurdles in navigating the coverage and reimbursement process. In fact, many technology manufacturers do not pursue national coverage decisions because they are too time consuming and cumbersome.  

CMS Rolls Back Harmful Proposals in Medicare Part D

Monday, May 20, 2019